Drug Hunter’s Post

There were 13 biopharma M&A deals in Q1 of 2024, more than doubling what we saw in Q1 of 2023. Radiopharmaceuticals and ADC are trending targets this year for acquisitions. Read more about #M&A trends in the Fierce Biotech article below. #biotech

🔍💼 Biopharma deal activity showed a slowdown in Q2. 📉 Notable acquisitions by Novartis, Biogen, and Merck & Co. stood out, while IPOs were scarce. Actuate Therapeutics, Rapport Therapeutics, and Alumis were among the biotechs gearing up for IPOs, with Telix Pharmaceuticals making a last-minute withdrawal. 💡 Stay tuned for more industry insights! #Biopharma #Deals #IPOs #Acquisitions #IndustryInsights 🚀

The pharmaceutical and biotech sectors have experienced a resurgence in mergers and acquisitions (M&A) activity since mid-2023, with significant deals such as Pfizer's $43 billion Seagen takeover highlighting the trend. Entering 2024, the momentum continued with Novo Nordisk's $16.5 billion acquisition of Catalent and Bristol Myers Squibb's multi-billion-dollar deals with Mirati Therapeutics and Karuna Therapeutics. To stay current with the dynamic M&A landscape, use BioSpace's M&A tracker. This valuable tool ensures you're informed about the latest consolidation moves shaping the industry landscape - from blockbuster acquisitions to strategic partnerships. #Pharmaceuticals #Biotech #MergersAndAcquisitions

Here we go again. With pharma companies partying like it's 1999, Biospace has launched a handy new tool for tracking M&A in the bio-pharma industry. Billions and billions bought! #Pharma #DrugMergers #5ForcesofHCT #HCTConsolidation "After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and biotech sectors has accelerated since the middle of last year, highlighted by Pfizer’s $43 billion takeover of Seagen. Since the calendar turned to 2024, we have seen some blockbusters, including Novo Nordisk's $16.5 billion purchase agreement for Catalent and the closing of Bristol Myers Squibb's $4.8 billion acquisition of Mirati Therapeutics and $14 billion takeover of Karuna Therapeutics."

We are continuing to see a high level of M&A activity in Q2 of this year. A number of small acquisitions took place last week, marking the continued trend of acquisitions in 2024 and lending to more diversification of some key players in #biotech. BioSpace gives more detail about this activity in the article below. #biotech #pharma

The number of biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and attention. 13 biopharma M&A deals in the first quarter of 2024 compared to six in the first quarter of 2023. 47 deals in the last twelve months through March 2024, compared to 42 through March 2023. #mergerandacquisition #investing #CEO #biopharma #wheretoinvest #druginnovation #artificialinyelligence

#News: The number of #biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and attention. A new report from Leerink Partners released this week tallied 13 biopharma M&A deals in the first quarter of 2024 compared to six in the first quarter of 2023. There were 47 deals in the last twelve months through March 2024, compared to 42 through March 2023. The Leerink M&A team described persistent #BigPharma interest specifically in #biotechs focusing on new #cancerdrugs, namely #radiopharmaceutical and #antibodydrugconjugate (#ADC) makers. AstraZeneca made two deals in the #oncology sphere while Merck offered bait to #Tcellengager company, Harpoon Therapeutics. The report’s authors conclude that they expect M&A activity to stay hot through the rest of the year. Elsewhere, #publiccompanies that struggled to produce stellar data were able to find #reversemerger partners, including Tectonic Therapeutic, Inc. ’s deal with AVROBIO and LENZ Therapeutics 's merger with Graphite Bio . The report notes that among 10 public-private mergers that have closed since the beginning of 2023, stock prices are up 29%. Read more from Fierce Biotech 👇🏽 https://lnkd.in/ejX_A5aN

Top 10 Biopharma Takeover Targets of 2024 Amid expectations for a rise in M&A activity, market watchers are keeping their eyes on #biopharma companies that are ripe for the taking. This A-List marks the first compilation of takeover targets by GEN's Alex Philippidis since the September 2019 A-List of top M&A prospects.

4 ADC Deals 9 days into 2024! Explore the financial details and terms through the provided hyperlinks. 🤝 WuXi XDC & IntoCell Inc: WuXi XDC embarks on a strategic Partnership Agreement with IntoCell to expedite ADC Discovery and Development. https://lnkd.in/eHa2zxu5 🌐 MediLink Therapeutics & Roche: Global Collaboration and Lincense Agreement for ADC YL211. MediLink stands to gain upfront and near-term milestone payments amounting to $50 million. Additionally, potential development, regulatory, and commercial milestones could elevate the total deal value to nearly $1 billion. https://lnkd.in/ezDyhquJ 📈 OnCusp Therapeutics: Successfully secures $100 million in Series A Financing. Co-led by Novo Holdings, OrbiMed, and F-Prime Capital.         https://lnkd.in/eVer6DYJ 🌐 The Janssen Pharmaceutical Companies of Johnson & Johnson & Ambrx: J&J Enters into a Definitive Agreement for the Acquisition of Ambrx Biopharma. Acquisition price: $28.00/share in cash, reflecting a 105% premium over Ambrx's closing stock price. https://lnkd.in/eG7uMBvi The ADC industry continues to witness impactful collaborations, substantial investments, and strategic acquisitions! #ADC #Biotech #antibodydrugconjugates #PharmaNews

🔍 **Biopharma Faces Patent Cliffs but Poised for Strong M&A Activity** 💊 Morgan Stanley's latest report reveals that while many top-selling biopharma products are approaching patent expirations, the industry is well-equipped for strategic acquisitions. With $383.1 billion in dealmaking potential, companies like J&J, Merck, and Novo Nordisk are positioned to navigate this challenge effectively. Key insights: - Products losing exclusivity through 2030 generate $183.5 billion annually. - Amgen, BMS, and Merck have the most revenue at risk. - Johnson & Johnson is best positioned with only 33% revenue exposure. Check out the full analysis by Terence Flynn, Ph.D., and the Morgan Stanley team for a deep dive into the industry's future: https://lnkd.in/gN7jMDHT #Biopharma #MergersAndAcquisitions #PharmaIndustry #MorganStanley #Innovation #HealthcareBusiness